OverviewSuggest Edit

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The Company's pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
TypePublic
Founded1983
HQHampton, US
Websitecelldex.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2019)127(-4%)
Job Openings3
Revenue (FY, 2019)$3.6 M(-62%)
Share Price (Sept 2020)$12.5
Cybersecurity ratingAMore

Key People/Management at Celldex Therapeutics

Anthony Marucci

Anthony Marucci

Founder, President & CEO
Anthony S. Marucci

Anthony S. Marucci

Founder, President, Chief Executive Officer and Director
Karen L. Shoos

Karen L. Shoos

Director
Tibor Keler

Tibor Keler

Founder, SVP & CSO
Keith L. Brownlie

Keith L. Brownlie

Director
Thomas Davis

Thomas Davis

CMO, EVP Clinical Development
Show more

Celldex Therapeutics Office Locations

Celldex Therapeutics has offices in Hampton, Fall River, Needham and New Haven
Hampton, US (HQ)
53 Frontage Rd #220
Fall River, US
UMass Dartmouth Center for Innovation & Entrepreneurship, 151 Martine St
Needham, US
119 4th Ave, Needham Heights
New Haven, US
300 George, 300 George St #530
Show all (4)

Celldex Therapeutics Financials and Metrics

Celldex Therapeutics Revenue

Celldex Therapeutics's revenue was reported to be $3.57 m in FY, 2019
USD

Revenue (Q2, 2020)

236.0k

Net income (Q2, 2020)

(11.0m)

EBIT (Q2, 2020)

(11.4m)

Market capitalization (22-Sept-2020)

487.1m

Closing stock price (22-Sept-2020)

12.5

Cash (30-Jun-2020)

68.0m

EV

422.1m
Celldex Therapeutics's current market capitalization is $487.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

9.3m11.2m4.1m3.6m5.5m6.8m12.7m9.5m3.6m

Revenue growth, %

(13%)53%24%

Cost of goods sold

700.0k100.0k

Gross profit

8.8m3.5m
USDQ2, 2011

Financial Leverage

1.3 x
Show all financial metrics

Celldex Therapeutics Operating Metrics

FY, 2016

Patents Issued

300
Show all operating metrics

Celldex Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Celldex Therapeutics Online and Social Media Presence

Embed Graph

Celldex Therapeutics News and Updates

Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock

HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public offering. Celldex is offering 13,377,926 shares of its common stock, par value $0.001 per share, at a…

Thinking about buying stock in Celldex Therapeutics, eMagin Corp, TOP Ships, Party City, or Alaska Air?

NEW YORK, June 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLDX, EMAN, TOPS, PRTY, and ALK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Celldex Therapeutics Announces Reverse Stock Split

HAMPTON, N.J., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary o…

Celldex Therapeutics Blogs

Celldex Provides Corporate Update and Reports First Quarter 2020 Results

HAMPTON, N.J. , May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020 . “Despite the ongoing challenges associated with the COVID-19 pandemic, Celldex continued to make considerable

Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020

HAMPTON, N.J. , May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of Allergy and Clinical Immunology (EAACI)

Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results

HAMPTON, N.J. , March 26, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2019 . “We are pleased that Celldex entered 2020 with significant momentum, following exciting data in late

Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program

Celldex also eligible to receive future milestone payments plus royalties HAMPTON, N.J. , March 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the Company will receive a $1.7 million payment related to an existing 2013 agreement with Rockefeller

Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study HAMPTON, N.J. , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers.

Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs

Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs Content Import Mon, 11/11/2019 - 08:01 Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs Nov 11, 2019 This release is a backfill from a News Wire General …
Show more

Celldex Therapeutics Frequently Asked Questions

  • When was Celldex Therapeutics founded?

    Celldex Therapeutics was founded in 1983.

  • Who are Celldex Therapeutics key executives?

    Celldex Therapeutics's key executives are Anthony Marucci, Anthony S. Marucci and Karen L. Shoos.

  • How many employees does Celldex Therapeutics have?

    Celldex Therapeutics has 127 employees.

  • What is Celldex Therapeutics revenue?

    Latest Celldex Therapeutics annual revenue is $3.6 m.

  • What is Celldex Therapeutics revenue per employee?

    Latest Celldex Therapeutics revenue per employee is $28.1 k.

  • Who are Celldex Therapeutics competitors?

    Competitors of Celldex Therapeutics include Biogen, Athersys and Otonomy.

  • Where is Celldex Therapeutics headquarters?

    Celldex Therapeutics headquarters is located at 53 Frontage Rd #220, Hampton.

  • Where are Celldex Therapeutics offices?

    Celldex Therapeutics has offices in Hampton, Fall River, Needham and New Haven.

  • How many offices does Celldex Therapeutics have?

    Celldex Therapeutics has 4 offices.